Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Kathrin Perrig¹, Niklas Krupka², Sebastian Bruno Ulrich Jordi³, Jean-Benoît Rossel⁴, Luc Biedermann¹, Thomas Greuter¹, Philipp Schreiner¹, Stephan R Vavricka⁵, Pascal Juillerat², Emanuel Burri⁶, Dorothee Zimmermann⁷, Michel H Maillard⁸, Michael Christian Sulz⁹, Stephan Brand¹⁰, Gerhard Rogler¹, Benjamin Misselwitz¹¹

Affiliations

¹ Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
² Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
³ Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, SwitzerlandDepartment of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
⁵ Center of Gastroenterology and Hepatology, Zurich, Switzerland.
⁶ Department of Gastroenterology and Hepatology, University Medical Clinic, Kantonsspital Baselland, Liestal, Switzerland.
⁷ Department of Gastroenterology, Kantonsspital Nidwalden, Stans, Switzerland.
⁸ Service of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland; Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.
⁹ Department of Gastroenterology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
¹⁰ Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
¹¹ Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Freiburgstr. 18, 3010 Bern, Switzerland.

PMID: 35154389
PMCID: PMC8832575
DOI: 10.1177/17562848221074188

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Kathrin Perrig et al. Therap Adv Gastroenterol. 2022.

. 2022 Feb 9:15:17562848221074188.

doi: 10.1177/17562848221074188. eCollection 2022.

Authors

Affiliations

¹ Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
² Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
³ Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, SwitzerlandDepartment of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
⁵ Center of Gastroenterology and Hepatology, Zurich, Switzerland.
⁶ Department of Gastroenterology and Hepatology, University Medical Clinic, Kantonsspital Baselland, Liestal, Switzerland.
⁷ Department of Gastroenterology, Kantonsspital Nidwalden, Stans, Switzerland.
⁸ Service of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland; Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.
⁹ Department of Gastroenterology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
¹⁰ Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
¹¹ Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Freiburgstr. 18, 3010 Bern, Switzerland.

PMID: 35154389
PMCID: PMC8832575
DOI: 10.1177/17562848221074188

Abstract

Background: Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab in a real-world setting in Switzerland.

Methods: We analyzed real-world data from 1769 UC patients from the Swiss Inflammatory Bowel Disease Cohort (SIBDC) study and performed a chart review of golimumab-treated patients. We extracted the partial Mayo score at t₀ (baseline), t₁ (2-16 weeks), t₂ (17-35 weeks), and t₃ (36-89 weeks). The primary endpoint was clinical response at t₁, defined as marked improvement in partial Mayo score and objective parameters. Clinical remission was defined as resolution of symptoms and normalization of objective parameters.

Results: Our chart review included 103 UC patients with golimumab treatment (5.8% of all SIBDC UC patients); only 16 (15.5%) were anti-TNF naïve. Sixty-three patients remained on golimumab (61.2%) after 180 days, 51 (44.7%) after 365 days, and 34 (33%) after 630 days after the start of treatment. Upon golimumab treatment, the partial Mayo score decreased from 4 [interquartile range (IQR): 2-6] at t₀ to 2 (IQR: 0-4) at t₁, 1 (IQR: 0-3.5) at t₂, and 1 (IQR: 0-3) at t₃ (p < 0.001 for all comparisons with t₀). The primary endpoint, clinical response at t₁, could be evaluated in 52 patients and was met in 15 individuals (28.8%). Clinical remission at t₁ was observed in 8 out of 52 patients (15.4%). Golimumab was generally well tolerated, one patient developed meningitis. The most frequent reasons to stop treatment were primary and secondary non-response.

Conclusion: Golimumab was used in 5.8% of Swiss UC patients, mainly in biologic-experienced individuals. Golimumab treatment was associated with a sustained reduction of symptoms and clinical response in approximately 30% of patients.[ClinicalTrials.gov identifier: NCT00488631].

Keywords: TNF inhibitor; golimumab; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KP has nothing to disclose. NK has nothing to disclose. SBUJ has nothing to disclose. JBR has nothing to disclose. LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, and Ewopharma. TG has consulting contracts with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. PS has consulted to Pfizer, Takeda, Abbvie, and Janssen-Cilag and received travel support from Falk and UCB. SRV has received consulting fees, speakers honorary, and unrestricted research grants from Abbott, Alfasigma, Amgen, Arenapharm, Falk Pharma GmbH, Ferring Pharmaceuticals, Gilead, iQuone, Janssen, MSD, Permamed, Pfizer Inc, Sanofi-Aventis, Takeda, Tillotts, UCB, and Vifor. PJ has received a research grant from Vifor unrelated to this work. EB received consultant and/or speaker fees from Abbvie, Janssen, MSD, Norgine, Pfizer, Sandoz, Takeda, and Vifor. DZ has nothing to disclose. MHM has received consultant fees from Vifor, Abbvie, UCB, MSD, Lilly, Janssen, and Takeda. He also received grants from UCB, Abbvie, Vifor, MSD, Takeda. He received speaker fess from Vifor, Janssen, Abbvie, MSD, Pfizer, UCB, and Takeda. MCS has received consultant and/or speaker fees from Abbvie, Ferring, MSD, Janssen, Pfizer, Takeda, UCB. SB has consulted to Abbvie, Celgene, Ferring, Gilead, Janssen, MSD, Pfizer, Roche, UCB, and Takeda, Vifor; SB has received speaker’s honoraria from Abbvie, FALK, Ferring, MSD, Takeda, UCB, and Vifor; SB has received an educational grant from Takeda. GR has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions, and Zeller; GR has received speaker’s honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor, and Zeller; GR has received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. BM has received a research grant from MSD for this work. BM has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD, and Takeda and traveling fees from Vifor, Novartis, Gilead, and Takeda.

Figures

**Figure 1.**
Flow chart and time course of patients treated with golimumab during follow-up. PMS, partial Mayo Score; SIBDC, Swiss Inflammatory Bowel Disease Cohort; UC, ulcerative colitis.

**Figure 2.**
Shifting patterns of treatment with biologics in patients of the Swiss IBD cohort (SIBDC) study with ulcerative colitis (UC).

**Figure 3.**
Clinical efficacy of golimumab treatment. The medians and interquartile ranges are indicated by bars. Statistical analysis: linear mixed-effects model calculating fixed effects of time. Significance for the time trend are indicated without multiple test correction: (*)p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, and after Bonferroni-correction for 10 independent tests in Figures 3 and 4: #q < 0.05; ##q < 0.01; ###q < 0.001; ####q < 0.0001. Mann–Whitney U test. MTWAI, modified Truelove and Witts activity index; PGA, physician’s general assessment.

**Figure 4.**
Changes in laboratory parameters upon golimumab treatment. The medians and interquartile ranges are indicated by bars. Statistical analysis: linear mixed-effects model calculating fixed effects of time. Significance for the time trend are indicated without multiple test correction: (*)p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, and after Bonferroni-correction for 10 independent tests in Figures 3 and 4: #q < 0.05; ##q < 0.01; ###q < 0.001; ####q < 0.0001. CRP, C-reactive protein.

See this image and copyright information in PMC

References

1. Cholapranee A, Hazlewood GS, Kaplan GG, et al.. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 2017; 45: 1291–1302. - PMC - PubMed
1. Singh S, Fumery M, Sandborn WJ, et al.. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 162–175. - PubMed
1. Misselwitz B, Juillerat P, Sulz MC, et al.. Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more. Digestion 2020; 101(Suppl. 1): 69–82. - PubMed
1. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24–30. - PubMed
1. Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016; 9: 513–526. - PMC - PubMed

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Affiliations

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Associated data

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous